Skip to main content

Table 1 Baseline characteristics and associated mortality among patients with chronic hepatitis B who started antiviral treatment in Ethiopia

From: Predictors of mortality in patients under treatment for chronic hepatitis B in Ethiopia: a prospective cohort study

Characteristics

Number of patients (%) (n = 276)

Number of deaths (%) (n = 35)

Sex

 Male

215 (77.9)

29 (82.9)

 Female

61 (22.1)

6 (17.1)

Age (years)

 18–25

58 (21.0)

4 (11.4)

 26–35

101 (36.6)

11 (31.4)

 36–45

63 (22.8)

9 (25.7)

  > 45

54 (19.6)

11 (31.4)

ALT (U/L)

  < 40

163 (59.1)

19 (54.3)

  40–79

78 (28.3)

11 (31.4)

  ≥ 80

35 (12.7)

5 (14.3)

Body mass index (kg/m2)a

  < 18.5

57 (21.2)

14 (41.2)

  ≥ 18.5

212 (78.8)

20 (58.8)

HBV viral load (IU/m)b

  < 2000

85 (30.8)

12 (34.3)

 2000-19,999

42 (15.2)

2 (5.7)

  ≥ 20,000

149 (54.0)

21 (60.0)

Transient elastography (kPa)

  < 8.0

50 (19.2)

1 (3.1)

 8.0–9.9

37 (14.2)

1 (3.1)

  ≥ 10.0

173 (66.5)

30 (93.8)

Cirrhosis assessment

 No cirrhosis

86 (31.2)

1 (2.9)

 Compensated cirrhosisd

74 (26.8)

1 (2.9)

 Decompensated cirrhosise

116 (42.0)

33 (94.3)

  1. an = 269; bn = 251; cn = 260. dDefined as transient elastography ≥10.0 kPa. eDefined as clinical/ultrasonographic evidence of ascites
  2. ALT alanine aminotransferase, HBV hepatitis B virus